Pharmaceuticals

AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL

SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data we...

2026-04-20 22:00 3993

Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows

* The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure * The standalone booth features STAgora simulation and an interactive touchscreen experience * An enhanced CURECA model is presented, illustrating next-generation automated labora...

2026-04-20 21:00 3479

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region

* With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner * Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions ...

2026-04-20 19:30 2741

Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026

SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myelom...

2026-04-20 18:45 3346

Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline

SAN DIEGO, April 20, 2026 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce itsparticipation in the AACR Annual Meeting 2026, taking place April 19–22, 2026 in San Diego, California. At the meeting, the ...

2026-04-20 16:17 3376

AlphaGen Therapeutics to Present Preclinical Studies of Two Next-Generation Alpha Therapies at AACR 2026

SHANGHAI, April 20, 2026 /PRNewswire/ -- AlphaGen Therapeutics (AlphaGen), a biopharmaceutical company that focuses on developing next-generation targeted alpha radiotherapies, today announced that it will present preclinical data on two advanced radiopharmaceutical programs at the 2026 Annual Me...

2026-04-20 14:57 3401

Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ

SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchange on April 17th, 2026, Beijing Time. Alamar (NASDAQ:ALMR) issued shares at a price of $17 per sha...

2026-04-20 10:36 6072

Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal

Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal SHANGHAI, April 20, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance" or the "Company") announces that CHEST, the official journal of the American College of Chest Physicians...

2026-04-20 09:00 4272

ACT Genomics Upgrades Clinically Recognized Genomic Test to 101-Gene Panel with 7-Day Turnaround

TAIPEI, April 20, 2026 /PRNewswire/ -- ACT Genomics today announced a significant upgrade to the ACTDrug® series, its next-generation sequencing (NGS) genomic profiling service. The updated panel now covers 101 clinically relevant genes and offers a seven-working-day turnaround time, designed to ...

2026-04-20 09:00 3645

CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company pr...

2026-04-20 08:15 4034

Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)

•  The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure VALBY, Denmark, April 20, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lund...

2026-04-20 01:29 3794

Ddrops® Supports Children's Healthy Growth at Dripping Colours Montessori Sports Day -- Every Step Toward a Healthier Future

KUALA LUMPUR, Malaysia, April 18, 2026 /PRNewswire/ -- Ddrops® participated in the annual Sports Day hosted by Dripping Colours Montessori on April 18, 2026, reinforcing its commitment to supporting children's healthy growth through active lifestyles and proper ...

2026-04-18 20:00 5698

Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs

SHANGHAI and HONG KONG, April 18, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune ...

2026-04-18 08:30 6838

Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application

Lunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to better support treatment decision-making. SEOUL, South ...

2026-04-18 03:00 9681

Penetrium Bioscience Unveils Breakthrough Mechanism Solving 137-Year-Old "Seed & Soil" Paradigm, Opening a New Era for Targeted Cancer Therapy

SEOUL, South Korea, April 17, 2026 /PRNewswire/ -- Penetrium Bioscience (KOSDAQ 187660) today announced compelling new scientific evidence demonstrating, for the first time at the cellular level, the underlying mechanism behind the long-standing "Seed & Soil" theory originally proposed by Stephen...

2026-04-17 15:48 5428

DOJ Drops All Charges Against Vasudha

The company welcomes dismissal of the case after maintaining its innocence for more than a year HYDERABAD, India, April 17, 2026 /PRNewswire/ -- Vasudha Pharma Chem Limited ("Vasudha" or the "Company"), a leading pharmaceutical bulk drug and intermediate manufacturing company, announced today th...

2026-04-17 02:32 3949

Crystal Pharmatech Becomes First Company in Asia-Pacific to Deploy Dedicated MicroED Platform Through Strategic Collaboration with ELDICO Scientific

Advancing industrialized Microcrystal Electron Diffraction (MicroED) capabilities for global drug development SUZHOU, China, April 16, 2026 /PRNewswire/ -- Crystal Pharmatech is a science-driven CRO/CDMO specializing in solid-state research, preformulation studies, and formulation development an...

2026-04-16 20:00 3259

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing

* Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over 20 years of specialized experience to support partners from early-stage to commercialization. * Ajinomoto Bio-Pharma Services is a leading provider of biopharmaceutical...

2026-04-16 20:00 3597

Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market

SHANGHAI, April 16, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has established a licensing and commercialization agreement with a strategic business partner ("the partner") in Malaysia for its...

2026-04-16 17:00 5711

Harbour BioMed Appoints Dr. Adam Zong as President

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, April 16, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced t...

2026-04-16 15:20 5139
1 ... 11121314151617 ... 343

Week's Top Stories